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I would like to submit our manuscript entitled “Bioengineered Porous Silicon
Nanoparticles@Macrophages Cell Membrane as Composite Platforms for Rheumatoid
Arthritis” by our group and collaborators for publication as a full paper in Advanced
Functional Materials.
Biohybrid vectors are becoming increasingly popular in the nanotechnology field. The
applications of such nanoparticles (NPs) range from vaccines for cancer therapy, to
toxin detoxification systems, to drug delivery systems, and to artificial organelles.
Autoimmune diseases develop when the body loses the tolerance towards the “self”,
initiating an immune response against cells or tissues. Rheumatoid arthritis (RA)
represents an autoimmune disease attacking the joints, leading to loss of function and
co-morbidities. The current treatments are based on the administration of
immunosuppressive agents or disease modifying drugs, all presenting systemic side
effects. Exploiting the advantages brought by the nanosize, NPs have been proposed
for the local delivery of therapeutics, through the extravasation through leaky
vasculature and sequestration by immune cells effect or being directly targeted to
folate receptor, to the site of diseases and to the cells involved in the diseases (e.g.,
macrophages). Moreover, NPs have been employed in the induction of immune
tolerance against self-reactive peptides in several autoimmune diseases, including RA.
Thereby, keeping in mind a future application of the developed platform for drug
delivery or vaccination for autoimmune diseases (and rheumatoid arthritis in particular),
KG-1 macrophages were selected as model cell source for the cytoplasmic membrane
vesicles. Macrophages are identified as one of the key players in the inflammation of
the joints, showing a complex population heterogeneity and serving as possible target
of future therapies aimed to their polarization towards an anti-inflammatory phenotype.
Here, we developed composite platforms made of PSi coated with cell membrane
vesicles derived from macrophages, investigating the parameters leading to stable
systems. Moreover, we analyzed these systems in terms of size, surface morphology,
and stability in different biological buffers, followed by the biological evaluation of
cytocompatibility and immunological profile.
A study of the parameters influencing the production of PSi@cytoplasmic membranes
was conducted. Positively charged PSi NPs showed a lower degree of encapsulation
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
due to the strong electrostatic interactions between the particles and the cell
membranes. As for the differences in the hydrophobicity of the surface of the NPs, they
had an impact on the choice of the medium employed in the extrusion and in the
additional procedures (tip sonication) required. The nanoplatforms showed acceptable
stability in physiological buffers, while in plasma and simulated synovial fluid greatly
enhanced the stability of the hydrophobic particles (UnTHCPSi). Moreover, the
cytocompatibility of the systems evaluated in different cell lines representing the cells
present in the target organs, blood vessel and the kidney and liver. The nanoplatforms
were compatible up to 48 h at concentrations ranging from 0.5 to 50 µg/mL. Finally, the
immunological profile investigated in KG-1 macrophages showed that PSi@KG-1
nanosystem did not result in the activation of the immune system and the coating of
UnTHCPSi particles with cell membranes attenuated the immunostimulative potential
of the particles. Overall, we developed, as proof of concept, two biohybrid
cytocompatible nanoplatforms as potential drug delivery systems or as antigen carriers
for the induction of tolerance against autoimmune diseases.
This work brings together several scientific areas, including materials science,
biomedical engineering, biomaterials, and rheumatoid arthritis. This new result is
completely covered within the scope of Advanced Functional Materials and is of timely
interest to the readers of this journal. We firmly believe that this manuscript is suitable
for publishing in Advanced Functional Materials.
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Abstract: Biohybrid nanosystems are at the center of personalized medicine, affording prolonged
circulation time and targeting to the disease site, and serving as antigenic sources of
vaccines. The optimization and functionality parameters of these nanosystems vary
depending on the properties of the core particles. In this work, the effects of the core
particles' surface charge and hydrophobicity are evaluated on the nanosystem coating
with vesicles derived from plasma membrane. The measured parameters are the
dimensions, surface charge, shape, and stability of the biohybrid nanosystems, both in
buffer and in biologically relevant media (plasma and simulated synovial fluid).
Moreover, the cytocompatibility properties of the developed nanosystems are
evaluated in different cell lines mimicking the target cell populations and other districts
of the body involved in the distribution and elimination of the nanoparticles. Finally, the
immunological profile of the particles is investigated, highlighting the absence of
immune activation promoted by the nanoplatforms.
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Biohybrid nanosystems are at the center of personalized medicine, affording prolonged 
circulation time and targeting to the disease site, and serving as antigenic sources of vaccines. 
The optimization and functionality parameters of these nanosystems vary depending on the 
properties of the core particles. In this work, the effects of the core particles’ surface charge 
and hydrophobicity are evaluated on the nanosystem coating with vesicles derived from 
plasma membrane. The measured parameters are the dimensions, surface charge, shape, and 
stability of the biohybrid nanosystems, both in buffer and in biologically relevant media 
(plasma and simulated synovial fluid). Moreover, the cytocompatibility properties of the 
developed nanosystems are evaluated in different cell lines mimicking the target cell 
populations and other districts of the body involved in the distribution and elimination of the 
nanoparticles. Finally, the immunological profile of the particles is investigated, highlighting 

















































































Biohybrid vectors are becoming increasingly popular in the nanotechnology field. The 
applications of such nanoparticles (NPs) range from vaccines for cancer therapy, to toxin 
detoxification systems, to drug delivery systems, and to artificial organelles.[1] The biohybrid 
nanosystems can be obtained either by binding nanoparticles to cells (e.g., red blood cells and 
T lymphocytes) or by coating the particles with vesicles derived from the cytoplasmic 
membrane.[2] Poly(D,L-lactide-co-glycolide) NPs and gold NPs/nanocages, all presenting as a 
common feature a negative surface potential, have been successfully encapsulated in red 
blood cells, platelets, and cancer cell membranes, displaying increased stability in plasma, 
extending the circulation time of the particles in vivo, targeting the tumor, or delivering tumor 
antigens to antigen presenting cells.[2a, 3]  
Porous silicon (PSi) is an inorganic material displaying interesting properties in different 
biomedical applications from the enhancement of the dissolution rate of poorly soluble drugs, 
to the oral delivery of macromolecules for the therapy of diabetes, to treatment of 
cardiovascular diseases, to targeted cancer chemotherapy, to in vivo biohybrid drug delivery 
systems (leukolike vectors), to immunotherapy.[4] We previously reported two systems 
encapsulated in cell membrane vesicles: these systems differ in the nature of the core 
particles.[5] In one case, carboxylic acid terminated PSi particles were directly co-extruded 
together with the cell membranes, while in the other thermally oxidized PSi NPs were first 
encapsulated within a polymeric layer and, then, extruded with the cell membranes.  We were 
intrigued by the need for extrusion in two different buffers (PBS pH 7.4 or purified water) for 
the two different systems, thereby we decided to systematically study the effect of surface 







































































Scheme 1. Schematic of the nanoplatforms. PSi nanoparticles are processed together with 
cytoplasmic membranes isolated from KG-1 macrophages. Image created with Servier 
Medical Art. 
 
Autoimmune diseases develop when the body loses the tolerance towards the “self”, initiating 
an immune response against cells or tissues.[6] Rheumatoid arthritis (RA) represents an 
autoimmune disease attacking the joints, leading to loss of function and co-morbidities.[7] The 
current treatments are based on the administration of immunosuppressive agents or disease 
modifying drugs, all presenting systemic side effects.[6a, 7] Exploiting the advantages brought 
by the nanosize, NPs have been proposed for the local delivery of therapeutics, through the 
extravasation through leaky vasculature and sequestration by immune cells (ELVIS) effect or 
being directly targeted to folate receptor, to the site of diseases and to the cells involved in the 
diseases (e.g., macrophages).[6b, 8] Moreover, NPs have been employed in the induction of 
immune tolerance against self-reactive peptides in several autoimmune diseases, including 





































































Thereby, keeping in mind a future application of the developed platform for drug delivery or 
vaccination for autoimmune diseases (and rheumatoid arthritis in particular), KG-1 
macrophages were selected as model cell source for the cytoplasmic membrane vesicles. 
Macrophages are identified as one of the key players in the inflammation of the joints, 
showing a complex population heterogeneity and serving as possible target of future therapies 
aimed to their polarization towards an anti-inflammatory phenotype.[10] Here, we developed 
composite platforms made of PSi coated with cell membrane vesicles derived from 
macrophages, investigating the parameters leading to stable systems. Moreover, we analyzed 
these systems in terms of size, surface morphology, and stability in different biological 
buffers, followed by the biological evaluation of cytocompatibility and immunological profile. 
 
2. Results and Discussion 
2.1. Development of the Platforms 
Undecylenic acid modified thermally hydrocarbonized PSi (UnTHCPSi) NPs were selected as 
example of negatively charged hydrophobic particles, while (3-aminopropyl)-triethoxysilane 
modified thermally carbonized PSi (APTS-TCPSi) NPs served as positively charged 
nanosystem. Moreover, TCPSi NPs represented a negatively charged hydrophilic system.[4e] 
The properties of the NPs in terms of average size and number of particles in 1 mg are 
presented in Table 2. The process of development of the nanoplatforms included different 
extrusion buffers (sucrose 0.3 M and Milli-Q water), and the use of tip sonication in different 
stages of the preparation process. As shown in Table 1, in the case of the hydrophobic, 
negatively charged UnTHCPSi, the use of a stabilizer (sucrose) and of a double tipsonication 
were needed to obtain homogenous populations of NPs with an average hydrodynamic 
diameter  of 302±188 nm, a PdI of 0.15±0.01, and a zeta ()-potential of –23.7±0.2 mV. In the 
case of the positively charged NPs, APTS-TCPSi, the discriminating variable in the choice of 





































































that presented the inversion of charge to –6.3±1.1 mV (from the positive of APTS-TCPSi to a 
slightly negative one). These NPs had an average hydrodynamic diameter of 304±100 nm, 
with a PdI of 0.31±0.04. The optimal parameters for these NPs resulted the same as for 
UnTHCPSi particles (sucrose 0.3 M and two rounds of tip sonication).  
As for the hydrophilic TCPSi NPs, Milli-Q water and a preliminary sonication to 
homogenously disperse the NPs before the extrusion were sufficient to obtain nanoplatforms 
with a size of 246±80 nm, a PdI of 0.18±0.03, and a negative surface charge with a ζ-potential 
of –22.1±5.2 mV. 
 
Table 1. Nanoplatform development and the effect of the extrusion buffers and tipsonication 
in different stages of the preparation process (before extrusion, after extrusion, before and 
after extrusion) on NPs size, PdI, and -potential. The nanoplatform chosen for the following 
experiments is identified by ++, while the outcome of the other variables is coded from – – 
(worst nanoplatform) to + (second best nanoplatform). The results of average size, PdI, and -
potential are presented as mean±s.d (n=3). 
 
PSi NPs Buffers Tip Sonication Size [nm] PDI ζ-potential [mV]  
APTS-TCPSi Sucrose 0.3 M Before aggregated / +8.8±1.3 –  – 
Before and After 304±100 0.30±0.040 –6.3±1.1 ++ 
Milli-Q water Before 334±20 0.30±0.049 +31.2±0.5 + 
Before and After aggregated / –5.7±7.1 – 
UnTHCPSi Sucrose 0.3 M Before 575±200 0.50±0.07 –21.2±0.3 – 
Before and After 303±200 0.15±0.007 –23.7±0.2 ++ 
Milli-Q water Before 649±300 0.24±0.2 –15.1±7.1 + 





































































TCPSi Milli-Q water No Sonication 410±180 0.5±0.1 –20.6±6.5 – 
After aggregated / –19.8±4.9 –  – 
Before 246±100 0.180±0.03 –22.1±5.2 ++ 
Sucrose 0.3 M Before 289±100 0.3±0.07 –23.0±5.9 + 
 
The shape of the nanoplatforms was then evaluated by transmission electron microscopy 
(TEM), as shown in Figure 1. The cell membrane encapsulation of APTS-TCPSi NPs was 
not complete (Figure 1a) as indicated also by the ζ-potential values. These NPs tend to 
aggregate (with dimensions > 1 µm) and the only partial cell membrane coating is clear from 
the difference in the surface shape between coated and uncoated regions. On the contrary, 
both for UnTHCPSi and TCPSi, the NPs were successfully encapsulated within the 
cytoplasmic membrane vesicles (Figure 1b and c). The size observed in TEM, analyzed with 
ImageJ, is in good agreement with the values obtained by dynamic light scattering (average of 






































































Figure 1. TEM micrographs of (a) APTS-TCPSi@KG-1, (b) UnTHCPSi@KG-1, and (c) 
TCPSi@KG-1. 
 
Furthermore, with the aim of confirming the presence of the cell membrane on the surface of 
the particles, we analyzed the samples with energy dispersive X-ray analysis in scanning 
electron microscope (SEM–EDX) to highlight the elemental composition of the sample. As 
shown in Figures S1-S3, the presence of phosphorous (P), derived from the phospholipids of 
the membrane, could not be confirmed in any of the samples, despite the presence of the 
membrane in the pictures. The peak of silicon (Si), however, was clearly identified. We 





































































concentration of P falls below the limit of detection of the instrument.[11] Thereby, in order to 
confirm the presence of the lipidic membrane, we quantified the amount of choline present in 
the samples (Figure 2). TCPSi@KG-1 NPs retain higher amount of phosphatidyl choline (2-
fold higher, p<0.0001) compared to UnTHCPSi@KG-1. 
 
Figure 2. Lipid assay. Concentration of choline in 1 mg of particles after extrusion, quantified 
with the kit to measure the content of phosphatidyl choline. The results are presented as 
mean±s.d. (n=3). The sample was analyzed with one-way ANOVA followed by Bonferroni 
post-test and the level of significance was set at the probability of **** p<0.0001. 
 
2.2. Stability Studies 
An important parameter in the development of nanosystems is their stability both in 
physiological solutions (for safe and easy administration) and in biological fluids (plasma, 
synovial fluid). First, we evaluated the behavior of the NPs by DLS in two different 
physiological solutions: phosphate-buffered saline (PBS) 1X and glucose 5.4%, pH 7.4 





































































while their dimensions slightly increase after 1 h of incubation with the buffer. The positively 
charged APTS-TCPSi, however, also due to the partially exposed particles surface, show a 
high tendency to aggregate. In the case of isotonic glucose solution, hydrophobic 
UnTHCPSi@KG-1 are highly stable for the complete duration of the experiment, while with 
both TCPSi@KG-1 and APTS-TCPSi@KG-1, the presence of the sugar in the solution results 
in aggregation of the nanosystems. 
The nanoplatform displaying a positive charge in the core of the biohybrid nanosystems 
showed the worst results in terms of stability, due to the only partial coating of the particles 
by the membranes. As previously reported for red blood cell membranes and positively 
charged polystyrene particles, the production of a nanosystem presenting a positively charged 
core encapsulated within a cell membrane is hampered by the presence of two opposite 
charges, the positive from the particles and the negative from the cell membranes.[12] Thereby, 
we focused the following experiments on the negatively charged particles, UnTHCPSi@KG-1 
and TCPSi@KG-1. 
The NPs intended to be administered intravenously should not aggregate in blood in order to 
prolong the circulation and take advantage of the extravasation through the ELVIS effect.[13] 
UnTHCPSi NPs not coated with the cytoplasmic membrane were not stable in fresh frozen 
plasma, aggregating to sizes > 1 µm immediately after being dispersed into it (Figure 3a). On 
the contrary, the presence of the cell membrane layer shields the particles, preventing the 
aggregation, and retaining an uniform size up to 2 h, with statistically significant differences 
compared to the uncoated particles. Interestingly, for TCPSi NPs (Figure 3b), the stabilizing 
effect of the cell membrane is weaker than the hydrophilicity of the surface, thus the coated 
and uncoated NPs displayed the same trend, with size values not statistically different. The 
size of both the systems, during the incubation with cytoplasmatic membranes increased to 
around 500 nm, with UnTHCPSi@KG-1 displaying lower standard deviation. The stabilizing 





































































hydrophobic surface, where the cell membrane stabilized the NPs, mimicking the cellular 
surface, while UnTHCPSi particles alone aggregate.[14]  
 
 
Figure 3. Stability of UnTCHPSi, UnTHCPSi@KG-1, TCPSi, and TCPSi@KG-1 systems in 
(a) and (b) human fresh frozen plasma, and (c) and (d) simulated synovial fluid, up to 2 h. The 
results are presented as mean±s.d. (n=3). The results were analyzed with two-way ANOVA, 
followed by Bonferroni’s post-test and the levels of significance were set at the probabilities 
of *p<0.05, **p<0.01, and *** p<0.001. 
 
Taking into account a possible intra-articular local administration, the stability of the 
biohybrid nanoplatforms in simulated synovial fluid was also evaluated.[15] However, as 
reported by a recent study, micro- and nano-particles administered locally, in the joint, will 





































































layer is limited for UnTHCPSi (Figure 3c), where the size of the coated particles increases to 
800 nm, while the uncoated NPs form aggregates of 1 µm. Finally, when TCPSi both coated 
and uncoated are suspended in simulated synovial fluid (Figure 3d), they exhibited a similar 
trend between each other, i.e., size increasing to 500–600 nm and remaining stable over 2 h. 
 
2.3. Biological Assays 
2.3.1. Cytocompatibility 
Next, the cytocompatibility of the nanosystems was evaluated in vitro. We firstly evaluated 
the compatibility of the two nanosystems in the cells used to isolate the cell membranes, i.e., 
KG-1 (Figure 4a). After 24 h, both coated and uncoated TCPSi were cytocompatible in the 
whole range of concentration assessed (0.5–500 µg mL-1), while UnTHCPSi@KG-1 were 
cytocompatible only for the lower concentrations, with uncoated UnTHCPSi displaying a 
lower toxicity for higher concentrations. The cytocompatibility of the developed 
nanoplatforms was then assessed on cell lines representative of the target fibroblasts, present 
in the joint, endothelial cells (EA.hy926) representative of the cells lining the blood vessels, 
renal cells (HEK-293) and hepatic cells (HepG2) for the two main excretion routes.[17] All the 
NPs were cytocompatible when exposed to human dermal fibroblasts (Figure 4b), while the 
particles exhibited a surface-dependent cytotoxicity in EA.hy926 cells (Figure 4c). TCPSi 
NPs, both coated and uncoated, exhibited cytotoxicity, with the coated nanosystems inducing 
reduced viability at the highest concentrations (50 and 500 µg mL-1). As for renal cells 
(Figure 4d), all the NPs induced a dose-dependent toxicity, particularly accentuated for both 
the coated and uncoated TCPSi NPs at the highest concentration assessed. Finally, in HepG2 
cells, the hydrophilic TCPSi NPs displayed higher cytocompatibility at the lower 
concentrations, while all the NPs reduced the viability to 60% of the negative control at the 






































































Figure 4. Cell viability (%) of (a) KG-1 cells, (b) human dermal fibroblast, (c) EA.hy926, (d) 





































































TCPSi@KG-1 at different concentrations for 24 h. Complete medium and Triton X-100 (1%) 
were used as negative and positive control, respectively. The results are presented as 
mean±s.d. (n≥3). The samples were analyzed with two-way ANOVA, followed by 
Bonferroni’s post-test and the levels of significance were set at the probabilities of ** p< 0.01 
and *** p<0.001. 
 
After 48 h of incubation, all the nanosystems resulted in a pronounced dose-dependent 
cytotoxicity on KG-1 macrophages (Figure 5a), starting from 50 µg mL-1 for 
UnTHCPSi@KG-1 and involving all the NPs at the highest concentration. Even after 
prolonged incubation, fibroblasts did not exhibit significant decrease in the cell viability due 
to the NPs, with all the nanosystems being cytocompatible over the whole range of 
concentrations tested (Figure 5b). The same trend was observed also in the endothelial cells, 
EA.hy926, where the surface-dependent difference seen for shorter incubation times (Figure 
4c) was not found for longer incubation times (Figure 5c). The effect of the incubation of the 
nanosystems for 48 h on HEK-293 displayed a dose-dependent cytotoxicity at the highest 
concentration assessed (500 µg mL-1), while at the lower concentrations they were 
cytocompatible (Figure 5d). Finally, after 48 h of incubation with the nanosystems, HepG2 
cells were more sensitive to the hydrophobic UnTHCPSi NPs both coated and uncoated, 










































































































































Figure 5. Cell viability (%) of (a) KG-1 cells, (b) human dermal fibroblast, (c) EA.hy926, (d) 
HEK-293, and (e) HepG2 incubated with UnTHCPSi, UnTHCPSi@KG-1, TCPSi, and 
TCPSi@KG-1 at different concentrations for 48 h. Complete medium and Triton X-100 (1%) 
represented the negative and positive control, respectively. The results are presented as 
mean±s.d. (n≥3). The samples were analyzed with two-way ANOVA, followed by 
Bonferroni’s post-test and the levels of significance were set at the probabilities of *p<0.05 
and *** p<0.001. 
 
2.3.2 Immunological Profile 
The nanosystems employed for the treatment of autoimmune diseases should exhibit an 
immunoneutral profile, avoiding a further activation of the immune system.[18] Thus, we 
sought to investigate the immunological profile of the developed nanoplatforms, before and 
after coating with the cytoplasmatic membranes. As shown in Figures 6a and c, after 48 and 
72 h of incubation, UnTHCPSi NPs induced a statistically significant (p<0.001) enhanced 
presentation of CD80 on KG-1 cells. However, the coating with cell membrane greatly 
reduced the immunostimulation to the levels of the control. It was previously shown that the 
hydrophobic surface of UnTHCPSi NPs is mildly stimulating antigen presenting cells (as 
measured by the presentation of co-stimulatory signals and the secretion of pro-inflammatory 
cytokines), while the hydrophilic surface of TCPSi NPs did not result in any activation 
input.[4e] As for CD86 (Figures 6b and d), all the nanosystems, except TCPSi, showed a 
significant difference compared to the control after 48 h, but not after longer incubation time 






































































Figure 6. Percentage of cells presenting CD80 after 48 h (a) and 72 h (c) or CD86 after 48 h 
(b) and 72 h (d). The cells were incubated with the nanosystems at a concentration of 50 µg 
mL-1 for 48 h or 72 h, and then stained with PE-antihuman CD80 and APC-antihuman CD86 
antibodies. The results are presented as mean±s.d (n=3). The data were analyzed by one-way 
ANOVA followed by Bonferroni’s post-test and the levels of significance were set at the 
probabilities of *p<0.05 and ***p<0.001. In (a) and (c) the samples of the UnTHCPSi NPs 
were compared to the sample UnTHCPSi@KG-1, while in (b) the samples were compared to 
the control (medium). 
 
3. Conclusion 
A study of the parameters influencing the production of PSi@cytoplasmic membranes was 
conducted. Positively charged PSi NPs showed a lower degree of encapsulation due to the 





































































differences in the hydrophobicity of the surface of the NPs, they had an impact on the choice 
of the medium employed in the extrusion and in the additional procedures (tip sonication) 
required. The nanoplatforms showed acceptable stability in physiological buffers, while in 
plasma and simulated synovial fluid greatly enhanced the stability of the hydrophobic 
particles (UnTHCPSi). Moreover, the cytocompatibility of the systems evaluated in different 
cell lines representing the cells present in the target organs, blood vessel and the kidney and 
liver. The nanoplatforms were compatible up to 48 h at concentrations ranging from 0.5 to 50 
µg mL-1. Finally, the immunological profile investigated in KG-1 macrophages showed that 
PSi@KG-1 nanosystem did not result in the activation of the immune system and the coating 
of UnTHCPSi particles with cell membranes attenuated the immunostimulative potential of 
the particles. Overall, we developed, as proof of concept, two biohybrid cytocompatible 
nanoplatforms as potential drug delivery systems or as antigen carriers for the induction of 
tolerance against autoimmune diseases. 
 
4. Experimental Section  
Preparation of PSi nanoparticles: Silicon NPs were prepared by electrochemical etching of Si 
wafers and their surface was subsequently modified to obtain  thermal hydrocarbonization 
followed by modification with an alkenoic acid (undecylenic acid, UnTHCPSi) to provide 
terminal carboxylic acid groups, or thermal carbonization (TCPSi) and thermal carbonization 
followed by a hydroxyl generation step and silanization using (3-aminopropyl)-triethoxysilane 
(APTS-TCPSi) to introduce available amine groups, as previously reported.[4a, 4b, 4d, 4e, 14a, 19] 
Nitrogen sorption at 196°C (TriStar 3000, Micromeritic, USA) was used to obtain the 
specific surface area (SSA) using the BET method and the total pore volume (at a relative 





































































Table 2. Surface modification, average hydrodynamic diameter, indicative number of NPs per 
mg of material, SSA, pore volume, and average pore diameter for each of the PSi NPs 
employed in this work. 
 











TCPSi Thermally Carbonized 159.8 9.96  1012 212±4 0.52±0.07 9.9±1.4 
UnTHCPSi Undecylenic Thermally 
Hydrocarbonized 






187.0 3.68  1012 331±8 0.89±0.07 11.1±0.7 
 
Cell lines: KG-1 macrophages (ATCC® CCL-246™) served as source of cell membrane, 
while we evaluated the cytocompatibility in human dermal fibroblasts, EA.hy926 (ATCC® 
CRL-2922™), HEK-293 (ATCC® CRL-1573™), and HepG2 (ATCC® HB-8065™). The 
cells were cultured according to the ATCC protocols. 
 
Isolation of cell membrane: We proceeded to the isolation of the cells membrane from KG-1 
macrophages as widely reported.[14, 15] Briefly, about 3  106 cells were washed three times 
with PBS 1X and resuspended in lysing buffer (Tris HCl, KCl, MgCl2, all from Sigma 






































































Preparation of PSi@KG-1 particles: PSi NPs were encapsulated within cell membrane 
vesicles by membrane extrusion (polycarbonate membrane, pore size 0.8 μm, Nucleopore 
Track-Etch Membrane, Whatman, UK) through an extruder (Avanti Polar Lipids Inc., USA). 
For the APTS-TCPSi@KG-1 NPs 1 mL of sucrose (0.3 M; Sigma Aldrich, USA) was 
employed to resuspend the cell membranes. 1 mg of PSi NPs were resuspended in this 
solution, tip sonicated (10 s, 30% amplitude; Ultrasonic Processor VCX series, Sonics and 
Material Inc., USA), and extruded for 21 passages. The solution collected from the extruded 
was tip sonicated a second time (10 s, 30% amplitude).  
For the TCPSi@KG-1 NPs the cell membranes were suspended in 1 mL of Milli-Q water 
(Millipore, USA). Then, 0.5 mg of the TCPSi particles were added, and the solution was tip 
sonicated (10 s, 30% amplitude) prior to extrusion for 21 passages. 
For the UnTHCPSi@KG-1 NPs the cell membranes were recovered in 1 mL of sucrose (0.3 
M, Sigma Aldrich, USA), added in 1 mg of UnTHCPSi NPs, and tip sonicated the solution 
(10 s, 30 % amplitude) before passing the sample through the extruder for 21 times. The 
solution recovered from the extruder was tip sonicated again, keeping the parameters constant. 
 
Lipid assay: In order to quantify the amount of lipid encapsulating the particles, we performed 
a lipid assay for the quantification of choline in the phosphocholine lipids in the membrane 
using a phosphatidylcholine assay kit (Sigma Aldrich, USA), according to the manufacturer’s 
instructions. Briefly, after incubation of the complete system with the reagents, the 
suspensions were centrifuged at 16 100 g, to separate PSi nanoparticles from the cell 
membrane lipids reacted. This step was performed in order to avoid interferences, deriving 
from the particles, in the fluorescence reading.  
 
Dynamic light scattering (DLS) and electrophoretic light scattering (ELS): The average 





































































formulations developed in different buffers were evaluated by DLS and ELS, using a 
Zetasizer Nano ZS (Malvern Instrument Ltd., UK). Briefly, 25 μL of particle solution (1 mg 
mL-1 for UnTHCPSi and APTS-TCPSi; 0.5 mg mL-1 for TCPSi) were diluted in 975 μL of 
Milli-Q water prior to each measurement.  
 
Transmission electron microscope (TEM): The shape of the nanosystems were imaged with a 
TEM (Jeol 1400, Japan) microscope at 80.0 KeV. In brief, about 5 μL of a solution containing 
the samples were applied to a carbon-coated copper grid (Electron Microscope FCF 200-CU 
Mesh Copper) for 5 min, before removing the excess with filter paper and overnight drying. 
The pictures were analyzed with ImageJ software (NIH, USA) to determine the size of the 
particles (10 particles measured for each sample). 
 
Scanning electron microscope (SEM) with energy dispersive X-rays (EDX) analysis: The 
elemental composition of the formulations was analyzed by EDX (Oxford INCA 350, Oxford 
Instruments, UK) connected with a SEM (Hitachi S-4800, Hitachi, Japan) at 30.0 KeV. The 
samples were applied to carbon-coated copper grids (as for the TEM imaging). 
 
Stability of the system in different buffers: The stability of the system in different buffers was 
evaluated by measuring the changes in size and surface potential upon incubation over time. 
Firstly, we investigated the stability up to 1 h in physiological buffers suitable for 
administration of the systems: PBS 1X and glucose 5.4% (pH 7.4). About 200 μL of each 
sample were added to 1 mL of the buffer solution. The samples were incubated at room 
temperature, with aliquots taken at different time points, up to 1 h. In order to evaluate the 
stability of the system in biological conditions following an intravenous administration, we 
tested the stability of the systems in fresh frozen plasma (provided by Finnish Red Cross), up 





































































μm sterile Acrodisc® Syringe Filters with Supor® Membrane, Pall Corporation, USA) before 
use. About 300 μL of each sample were pipetted in 1.5 mL of fresh frozen plasma, and stirred 
at 200 rpm and 37°C. Aliquots were taken at different times during the incubation period. 
Finally, with the aim of a possible application in rheumatoid arthritis, the behavior of the 
nanosystems in simulated synovial fluid (SSF) was also evaluated. Simulated synovial fluid 
was prepared as previously described.[23] In particular, we used the buffer prepared with 
modified Hank’s Balanced Salt Solution–N-[2-hydroxyethyl]piperazine-N’-[2-ethanesulfonic 
acid] (HBSS–HEPES, 0.14 M of NaCl; 5.4 mM of KCl; 1.62 mM of CaCl2; 4.16 mM of 
NaHCO3; 2.7 mM of Na2HPO4.2H2O; 0.49 mM of MgCl2.6H2O; without glucose; pH 8.0; all 
the chemicals are from Sigma Aldrich, USA) and bovine serum albumin (4 mg mL-1, Sigma 
Aldrich, USA), pH 8.0. The SFF was filtered with a 0.2 μm filter (0.2 μm sterile Acrodisc® 
Syringe Filters with Supor® Membrane, Pall Corporation, USA) before use. About 300 μL of 
each sample were pipetted in 1.5 mL of SSF and stirred at 200 rpm and 37°C. Aliquots were 
taken at different time points, up to 2 h. 
 
Cytocompatibility assay: The cytocompatibility of the nanosystems was evaluated on the 
following cell lines: KG-1, human dermal fibroblasts, EA.hy926, HEK-293, and HepG2. 
Complete medium and Triton X-100 (1%) were used as negative and positive control, 
respectively. In brief, adherent cells were seeded at the density of about 2  105 cells per mL 
in 96-well plates (Corning, USA) and left attaching overnight. The samples were diluted in 
complete medium. The medium was removed from the well, the samples were added to the 
appropriate wells, and the plate was incubated at 37°C. For KG-1, about 50 μL of a 4  105 
cells per mL were added to each well, followed by 50 μL of the samples at double 
concentration and the plate was then incubated at 37°C. 
We assessed the effect of the formulation on the cellular viability by an ATP-luciferase assay 





































































the medium was removed and the wells were washed twice with HBSS–HEPES (pH 7.4), 
before adding 100 μL of a 1:1 CellTiter Glo®:HBSS–HEPES solution to each well. In the case 
of KG-1, 100 μL of CellTiter Glo® were added to each well directly. The luminescence was 
then read with a Varioskan Lux multimodal plate reader (Thermo Fisher, USA).  
 
Immunological profile of the NPs: We evaluated the immunological profile of the 
formulations by measuring the changes in the expression of co-stimulatory markers, CD80 
and 86, in KG-1 macrophages. KG-1 were seeded at a density of 4  105 cells per mL in 12-
well plates (Corning, USA) and the samples, at double concentration, were added to the 
appropriate wells. Complete medium and LPS (100 ng mL-1) were used as negative and 
positive control, respectively. The cells were then incubated for 48 or 72 h. We centrifuged 
the cells and stained them with anti-human CD80-PE and CD86-APC antibodies (BD 
Biosciences, USA), washed twice and analyzed them with LSR II flow cytometer (BD 
Biosciences, USA). 
 
Statistical analysis: We report the results as mean ± s.d. (n≥3). The data were analyzed with 
two-way ANOVA followed by the Bonferroni post-test or one-way ANOVA followed by the 
Bonferroni post-test, as indicated in the Figures’ caption, using Graphpad Prism 5 (GraphPad 
Software Inc, USA). The levels of significance were set at probabilities of *p<0.05, **p<0.01 
and ***p<0.001. 
 
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
 
Acknowledgements 
H.A.S. acknowledges financial support from the University of Helsinki Research Funds, the 





































































European Research Council under the European Union’s Seventh Framework Programme 
(FP/2007-2013, grant no. 310892). 
 
Conflict of Interest 
The authors declare no conflict of interest. 
 
 
Received: ((will be filled in by the editorial staff)) 
Revised: ((will be filled in by the editorial staff)) 
Published online: ((will be filled in by the editorial staff)) 
 
References 
[1] S. Banskota, P. Yousefpour, A. Chilkoti, Macromol Biosci 2017, 17. 
[2] a) C. M. Hu, L. Zhang, S. Aryal, C. Cheung, R. H. Fang, L. Zhang, Proc Natl Acad 
Sci U S A 2011, 108, 10980; b) E. Chambers, S. Mitragotri, J Control Release 2004, 
100, 111; c) M. T. Stephan, S. B. Stephan, P. Bak, J. Chen, D. J. Irvine, Biomaterials 
2012, 33, 5776. 
[3] a) R. H. Fang, C. M. Hu, B. T. Luk, W. Gao, J. A. Copp, Y. Tai, D. E. O'Connor, L. 
Zhang, Nano Lett 2014, 14, 2181; b) W. Gao, C. M. Hu, R. H. Fang, B. T. Luk, J. Su, 
L. Zhang, Adv Mater 2013, 25, 3549; c) C. M. Hu, R. H. Fang, K. C. Wang, B. T. Luk, 
S. Thamphiwatana, D. Dehaini, P. Nguyen, P. Angsantikul, C. H. Wen, A. V. Kroll, C. 
Carpenter, M. Ramesh, V. Qu, S. H. Patel, J. Zhu, W. Shi, F. M. Hofman, T. C. Chen, 
W. Gao, K. Zhang, S. Chien, L. Zhang, Nature 2015, 526, 118; d) J.-G. Piao, L. Wang, 
F. Gao, Y.-Z. You, Y. Xiong, L. Yang, ACS Nano 2014, 8, 10414. 
[4] a) M. P. A. Ferreira, S. Ranjan, S. Kinnunen, A. Correia, V. Talman, E. Makila, B. 
Barrios-Lopez, M. Kemell, V. Balasubramanian, J. Salonen, J. Hirvonen, H. Ruskoaho, 
A. J. Airaksinen, H. A. Santos, Small 2017, 13; b) N. Shrestha, F. Araújo, M. A. 
Shahbazi, E. Mäkilä, M. J. Gomes, B. Herranz‐Blanco, R. Lindgren, S. Granroth, E. 
Kukk, J. Salonen, Adv Funct Mater 2016, 26, 3405; c) M.-A. Shahbazi, N. Shrestha, E. 
Mäkilä, F. Araújo, A. Correia, T. Ramos, B. Sarmento, J. Salonen, J. Hirvonen, H. A. 
Santos, Nano Research 2015, 8, 1505; d) B. Herranz‐Blanco, D. Liu, E. Mäkilä, M. 
A. Shahbazi, E. Ginestar, H. Zhang, V. Aseyev, V. Balasubramanian, J. Salonen, J. 
Hirvonen, Adv Funct Mater 2015, 25, 1488; e) M. A. Shahbazi, T. D. Fernandez, E. M. 
Makila, X. Le Guevel, C. Mayorga, M. H. Kaasalainen, J. J. Salonen, J. T. Hirvonen, 
H. A. Santos, Biomaterials 2014, 35, 9224; f) A. Parodi, N. Quattrocchi, A. L. Van De 
Ven, C. Chiappini, M. Evangelopoulos, J. O. Martinez, B. S. Brown, S. Z. Khaled, I. 
K. Yazdi, M. V. Enzo, Nature Nanotechnol 2013, 8, 61. 
[5] a) V. Balasubramanian, A. Correia, H. Zhang, F. Fontana, E. Mäkilä, J. Salonen, J. 
Hirvonen, H. A. Santos, Adv Mater 2017, 29; b) F. Fontana, M. A. Shahbazi, D. Liu, 
H. Zhang, E. Makila, J. Salonen, J. T. Hirvonen, H. A. Santos, Adv Mater 2017, 29. 
[6] a) L. Northrup, M. A. Christopher, B. P. Sullivan, C. Berkland, Adv Drug Deliv Rev 
2016, 98, 86; b) P. Serra, P. Santamaria, Clin Immunol 2015, 160, 3. 





































































[8] a) S. Dolati, S. Sadreddini, D. Rostamzadeh, M. Ahmadi, F. Jadidi-Niaragh, M. 
Yousefi, Biomed Pharmacother 2016, 80, 30; b) E. Nogueira, A. C. Gomes, A. Preto, 
A. Cavaco-Paulo, Nanomedicine 2016, 12, 1113. 
[9] X. Clemente-Casares, J. Blanco, P. Ambalavanan, J. Yamanouchi, S. Singha, C. 
Fandos, S. Tsai, J. Wang, N. Garabatos, C. Izquierdo, S. Agrawal, M. B. Keough, V. 
W. Yong, E. James, A. Moore, Y. Yang, T. Stratmann, P. Serra, P. Santamaria, Nature 
2016, 530, 434. 
[10] I. A. Udalova, A. Mantovani, M. Feldmann, Nat Rev Rheumatol 2016, 12, 472. 
[11] S. G. Wolf, P. Rez, M. Elbaum, J Microsc 2015, 260, 227. 
[12] B. T. Luk, C.-M. J. Hu, R. H. Fang, D. Dehaini, C. Carpenter, W. Gao, L. Zhang, 
Nanoscale 2014, 6, 2730. 
[13] a) A. Sen Gupta, Wiley Interdiscip Rev Nanomed Nanobiotechnol 2016, 8, 255; b) C. 
Li, H. Li, Q. Wang, M. Zhou, M. Li, T. Gong, Z. Zhang, X. Sun, J Control Release 
2017, 246, 133. 
[14] a) M. A. Shahbazi, P. V. Almeida, E. M. Makila, M. H. Kaasalainen, J. J. Salonen, J. 
T. Hirvonen, H. A. Santos, Biomaterials 2014, 35, 7488; b) J. S. Gebauer, M. 
Malissek, S. Simon, S. K. Knauer, M. Maskos, R. H. Stauber, W. Peukert, L. Treuel, 
Langmuir 2012, 28, 9673. 
[15] N. Diomidis, S. Mischler, N. More, M. Roy, S. Paul, Wear 2011, 271, 1093. 
[16] J. Pradal, P. Maudens, C. Gabay, C. A. Seemayer, O. Jordan, E. Allemann, Int J 
Pharm 2016, 498, 119. 
[17] a) C. He, Y. Hu, L. Yin, C. Tang, C. Yin, Biomaterials 2010, 31, 3657; b) L. Huo, R. 
Chen, L. Zhao, X. Shi, R. Bai, D. Long, F. Chen, Y. Zhao, Y. Z. Chang, C. Chen, 
Biomaterials 2015, 61, 307; c) M. C. Kraan, J. J. Haringman, H. Weedon, E. C. Barg, 
M. D. Smith, M. J. Ahern, T. J. Smeets, F. C. Breedveld, P. P. Tak, Ann Rheum Dis 
2004, 63, 483; d) A. Mor, S. B. Abramson, M. H. Pillinger, Clin Immunol 2005, 115, 
118. 
[18] M. Gharagozloo, S. Majewski, M. Foldvari, Nanomedicine 2015, 11, 1003. 
[19] L. M. Bimbo, M. Sarparanta, H. A. Santos, A. J. Airaksinen, E. Makila, T. Laaksonen, 







































































Biomimetic nanoplatforms composed of porous silicon particles and vesicles derived 
from the cytoplasmatic membrane of macrophages are developed. The platforms are 
characterized in terms of size, surface charge, and uniformity of coating. The stability of the 
systems in physiological fluids is investigated, highlighting an improvement after coating 
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